[{"indications": "Indications\u00a0suppression of inflammatory and allergic\r\ndisorders; congenital adrenal hyperplasia; see also notes above; ear\r\n(section\r\n12.1.1); eye (section 11.4.1); nose (section 12.2.1); oral ulceration (section 12.3.1)", "name": "BETAMETHASONE - GLUCOCORTICOID THERAPY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.3 Corticosteroids", "6.3.2 Glucocorticoid therapy", "BETAMETHASONE"], "cautions": "Cautions\u00a0\n(From Cautions and contra-indications of corticosteroids: British National Formulary)\nCautions and contra-indications of corticosteroids", "side-effects": "Side-effects\u00a0\n(From Side-effects of corticosteroids: British National Formulary)\nSide-effects of corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4267.htm", "doses": ["By mouth, usual range 0.5\u20135\u00a0mg daily; see\r\nalso Administration (above)", "By intramuscular injection or slow intravenous injection or infusion, 4\u201320\u00a0mg, repeated up to 4 times in 24 hours; child, by slow intravenous injection, up to 1 year 1\u00a0mg, 1\u20135 years 2\u00a0mg, 6\u201312 years 4\u00a0mg, repeated up\r\nto 4 times in 24 hours according to response"], "pregnancy": "Pregnancy\u00a0\n(From Pregnancy and breast-feeding: British National Formulary)\nPregnancy and breast-feeding; transient\r\neffect on fetal movements and heart rate"}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "BETAMETHASONE With neomycin", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids", "BETAMETHASONE", "With neomycin"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5420.htm", "doses": ["Apply eye drops every 1\u20132 hours until controlled then\r\nreduce frequency; apply eye ointment 2\u20134 times daily or at night when used with eye drops", "Name[Betnesol-N\u00ae (UCB Pharma) ] Drops (for ear, eye, or nose), see section\r\n12.1.1Dose\u00a0apply up to 6 times daily"]}, {"indications": "Indications\u00a0severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potent corticosteroids; psoriasis,\r\n\n(From 13.4 Topical corticosteroids: British National Formulary)\n13.4 Topical corticosteroids", "name": "BETAMETHASONE ESTERS With antimicrobials", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "BETAMETHASONE ESTERS", "With antimicrobials"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.; use of more than 100\u00a0g per week\r\nof 0.1% preparation likely to cause adrenal suppression", "side-effects": "Side-effects\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nSide-effects\u00a0Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing\u2019s syndrome (section 6.3.2), depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion. Local side-effects include:spread and worsening of untreated infection;thinning of the skin which may be restored over a period after stopping treatment but the original structure may never return;irreversible striae atrophicae and telangiectasia;contact dermatitis;perioral dermatitis;acne, or worsening of acne or rosacea;mild depigmentation which may be reversible;hypertrichosis also reported.In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5886.htm", "doses": ["Apply thinly 1\u20132 times daily", "Name[Fucibet\u00ae (LEO) ] Cream, betamethasone (as valerate) 0.1%, fusidic acid 2%, net price\r\n30\u00a0g = \u00a35.29, 60\u00a0g = \u00a310.58. \r\n    Label:\r\n    28, counselling, application. Potency: potentExcipients  include cetostearyl\r\nalcohol, chlorocresol\nLipid cream, betamethasone (as valerate)\r\n0.1%, fusidic acid 2%, net price 30\u00a0g = \u00a35.62. \r\n    Label:\r\n    28, counselling, application. Potency: potentExcipients  include cetostearyl alcohol, hydroxybenzoates\r\n(parabens)"]}, {"indications": "Indications\u00a0severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potent corticosteroids; psoriasis,\r\n\n(From 13.4 Topical corticosteroids: British National Formulary)\n13.4 Topical corticosteroids", "name": "BETAMETHASONE ESTERS With salicylic acid", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "BETAMETHASONE ESTERS", "With salicylic acid"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.; use of more than 100\u00a0g per week\r\nof 0.1% preparation likely to cause adrenal suppression", "side-effects": "Side-effects\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nSide-effects\u00a0Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing\u2019s syndrome (section 6.3.2), depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion. Local side-effects include:spread and worsening of untreated infection;thinning of the skin which may be restored over a period after stopping treatment but the original structure may never return;irreversible striae atrophicae and telangiectasia;contact dermatitis;perioral dermatitis;acne, or worsening of acne or rosacea;mild depigmentation which may be reversible;hypertrichosis also reported.In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5882.htm", "doses": ["Apply thinly 1\u20132 times daily", "apply a few drops 1\u20132 times daily", "Name[Diprosalic\u00ae (Schering-Plough) ] Ointment, betamethasone (as dipropionate) 0.05%, salicylic acid 3%, net\r\nprice 30\u00a0g = \u00a33.18, 100\u00a0g = \u00a39.14. \r\n    Label:\r\n    28, counselling, application. Potency: potent Excipients  none as listed in section 13.1.3Dose\u00a0apply thinly 1\u20132 times daily; max. 60\u00a0g per week\nScalp application, betamethasone (as dipropionate) 0.05%, salicylic acid 2%, in\r\nan alcoholic basis, net price 100\u00a0mL = \u00a310.10. \r\n    Label:\r\n    28, counselling, application. Potency: potentExcipients  include disodium\r\nedetateDose\u00a0apply a few drops 1\u20132 times daily"]}, {"indications": "Indications\u00a0non-infected inflammatory\r\nconditions of nose", "name": "BETAMETHASONE SODIUM PHOSPHATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.2 Drugs acting on the nose", "12.2.1 Drugs used in nasal allergy", "Corticosteroids", "BETAMETHASONE SODIUM PHOSPHATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, and also after nasal surgery (until healing has occurred); they should also be avoided in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids, see section 6.3.2. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local side-effects include dryness, irritation of nose and throat, and epistaxis. Nasal ulceration has been reported, but occurs commonly with nasal preparations containing fluticasone furoate or mometasone furoate. Nasal septal perforation (usually following nasal surgery) occurs very rarely. Raised intra-ocular pressure or glaucoma may occur rarely. Headache, smell and taste disturbances may also occur. Hyperactivity, sleep disturbances, anxiety, depression, and aggression have been reported particularly in children. Hypersensitivity reactions, including bronchospasm, have been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5646.htm", "doses": ["nose, 2\u20133 drops into each nostril twice\r\ndaily; ear, section\r\n12.1.1; eye, section 11.4.1"]}, {"indications": "Indications\u00a0eczematous inflammation in otitis\r\nexterna (\n(From 12.1.1 Otitis externa: British National Formulary)\n12.1.1 Otitis externa)", "name": "BETAMETHASONE SODIUM PHOSPHATE - ANTI-INFLAMMATORY PREPARATIONS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.1 Drugs acting on the ear", "12.1.1 Otitis externa", "Anti-inflammatory preparations", "Corticosteroids", "BETAMETHASONE SODIUM PHOSPHATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Prolonged use of topical corticosteroid ear preparations should be avoided.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local sensitivity reactions may occur.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31393.htm", "doses": ["ear, apply 2\u20133 drops every 2\u20133 hours; reduce\r\nfrequency when relief obtained; eye, section 11.4.1; nose, section 12.2.1"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "BETAMETHASONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5418.htm", "doses": ["Apply eye drops every 1\u20132 hours until controlled then\r\nreduce frequency; apply eye ointment 2\u20134 times daily or at night when used with eye drops"]}, {"indications": "Indications\u00a0non-infected inflammatory\r\nconditions of nose", "name": "BETAMETHASONE SODIUM PHOSPHATE - DRUGS USED IN NASAL ALLERGY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.2 Drugs acting on the nose", "12.2.1 Drugs used in nasal allergy", "Corticosteroids", "BETAMETHASONE SODIUM PHOSPHATE"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, and also after nasal surgery (until healing has occurred); they should also be avoided in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids, see section 6.3.2. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local side-effects include dryness, irritation of nose and throat, and epistaxis. Nasal ulceration has been reported, but occurs commonly with nasal preparations containing fluticasone furoate or mometasone furoate. Nasal septal perforation (usually following nasal surgery) occurs very rarely. Raised intra-ocular pressure or glaucoma may occur rarely. Headache, smell and taste disturbances may also occur. Hyperactivity, sleep disturbances, anxiety, depression, and aggression have been reported particularly in children. Hypersensitivity reactions, including bronchospasm, have been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5645.htm", "doses": ["nose, 2\u20133 drops into each nostril 2\u20133 times\r\ndaily; ear, section\r\n12.1.1; eye, section 11.4.1"]}, {"indications": "Indications\u00a0eczematous inflammation in otitis\r\nexterna (\n(From 12.1.1 Otitis externa: British National Formulary)\n12.1.1 Otitis externa)", "name": "BETAMETHASONE SODIUM PHOSPHATE With antibacterial", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.1 Drugs acting on the ear", "12.1.1 Otitis externa", "Anti-inflammatory preparations", "Corticosteroids", "BETAMETHASONE SODIUM PHOSPHATE", "With antibacterial"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Prolonged use of topical corticosteroid ear preparations should be avoided.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local sensitivity reactions may occur.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31395.htm", "doses": ["Name[Betnesol-N\u00ae (UCB Pharma) ] Drops (for ear, eye, or nose), betamethasone sodium phosphate 0.1%, neomycin\r\nsulphate 0.5%. Net price 10\u00a0mL = \u00a32.39Excipients  include benzalkonium chloride, disodium edetateDose\u00a0ear, apply 2\u20133 drops 3\u20134 times daily; eye, section 11.4.1; nose, section 12.2.3"]}, {"indications": "Indications\u00a0severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potent corticosteroids; psoriasis,\r\n\n(From 13.4 Topical corticosteroids: British National Formulary)\n13.4 Topical corticosteroids", "name": "BETAMETHASONE ESTERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "BETAMETHASONE ESTERS"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.; use of more than 100\u00a0g per week\r\nof 0.1% preparation likely to cause adrenal suppression", "side-effects": "Side-effects\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nSide-effects\u00a0Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushing\u2019s syndrome (section 6.3.2), depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion. Local side-effects include:spread and worsening of untreated infection;thinning of the skin which may be restored over a period after stopping treatment but the original structure may never return;irreversible striae atrophicae and telangiectasia;contact dermatitis;perioral dermatitis;acne, or worsening of acne or rosacea;mild depigmentation which may be reversible;hypertrichosis also reported.In order to minimise the side-effects of a topical corticosteroid, it is important to apply it thinly to affected areas only, no more frequently than twice daily, and to use the least potent formulation which is fully effective.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5883.htm", "doses": ["Apply thinly 1\u20132 times daily"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "BETAMETHASONE - CORTICOSTEROIDS AND OTHER ANTI-INFLAMMATORY PREPARATIONS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5418.htm", "doses": ["Apply eye drops every 1\u20132 hours until controlled then\r\nreduce frequency; apply eye ointment 2\u20134 times daily or at night when used with eye drops"]}]